Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial G (Q56784798)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial G	article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Pier Luigi Zinzani

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Michael Pfreundschuh

1

object named as

Michael Pfreundschuh

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Anthony D Ho

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Eva Cavallin-Stahl

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Max Wolf

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Ruth Pettengell

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Ingrid Vasova

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Andrew Belch

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Walter Mingrone

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Stein Kvaloy

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Ofer Shpilberg

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Ulrich Jaeger

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Mads Hansen

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Claudia Corrado

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Adriana Scheliga

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Markus Loeffler

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Evelyn Kuhnt

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

MabThera International Trial (MInT) Group

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

0 references

publication date

8 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

435-444

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Large-cell Lymphoma: A Study of Prognostic Factors and Assessment of Five Recently Proposed Predictive Systems

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in localized aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Stage I and II aggressive B-cell lymphomas of the head and neck: radiotherapy alone as a treatment option and the usefulness of the new prognostic index B-ALPS.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970078-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(08)70078-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18400558%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56784798&oldid=1829738741"